Acasti Pharma placed under review by Mackie Research Capital

Jan 13 21:01 2020 Print This Article

Disappointing results for its lead product candidate CaPre have led Mackie research capital analyst André Uddin to place Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) under review. This morning, Acasti reported topline results for Trilogy 1 Phase Three trail of CaPre that saw the company miss the primary endpoint due to an unexplained […]

The post Acasti Pharma placed under review by Mackie Research Capital appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

“E” vs “SG” in ethical investing: how sustainable is mollification-by-cherrypicking

In the great game of whack-a-mole that is capital raising in Canada’s oil patch, it must be frustrating, for those whose full-time job when there isn’t a global pandemic is whacking the moles of ESG criteria on which they feel their companies may be vulnerable to criticism and hence subject to ...

The LawBytes Podcast, Episode 52: Fair Dealing for Film Makers – Bob Tarantino on the Copyright Implications of the Room Full of Spoons Case

Dubbed by some as the worst film ever made, The Room has become a cult-like film classic. Written, directed, produced and starring Tommy Wiseau, the movie was the subject of the 2017 film The Disaster Artist and a documentary titled Room Full of Spoons by Canadian documentary filmmakers who wanted ...

The LawBytes Podcast, Episode 54: Eric Goldman on Internet Platform Liability and the Trump Executive Order

The U.S. approach to Internet platform liability has been characterized as the single most important legal protection for free speech on the Internet. Over the past two decades, every major Internet service has turned to the rules to ensure that liability for third party content posted on their sit ...

CASL is Constitutional: Federal Court of Appeal Upholds Constitutionality of Canada’s Anti-Spam Law

Canada’s anti-spam law has been the target of intense criticism since its introduction in 2009 as the Electronic Commerce Protection Act. Even after the law passed in 2010, there was no shortage of effort to delay the regulations needed to put it into effect. Once it finally took effect in 2014, ...

Customer Success: Formulary Management

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate… The post Customer Success: Formulary Management appeared first on DrugPatentW ...

Ottawa postpones short-sighted drug-pricing regulations

Author: Bacchus Barua Planned changes would likely result in fewer new and innovative drugs available to Canadians. Read more about Ottawa postpones short-sighted drug-pricing regulations Tags:  pmprb pharmaceutical drugs pharmaceutical innovation prescription drug prices ...

There’s still upside to Aurinia Pharma, says Mackie Research

All eyes are on a 2021 launch of voclosporin, lead candidate from drug developer Aurinia Pharmaceuticals (Aurinia Pharma Stock Quote, Chart, News NASDAQ:AUPH), but the stock received a target price trim from analyst André Uddin of Mackie Research on Friday, going from $24.00 to $22.00 per share. V ...

GW Pharmaceuticals is a world leader, AltaCorp Capital says

As the world’s first company to commercialize a plant-based cannabinoid-derived pharmaceutical, GW Pharmaceuticals (GW Pharmaceuticals Stock Quote, Chart, News NASDAQ:GWPH) stands out as a Top Pick for 2020, according to David M. Kideckel, analyst for AltaCorp Capital, who stayed bullish on the n ...

MedX Health has tons of upside, says Beacon Securities

Beacon Securities analyst Doug Cooper thinks the market has so far ignored a series of recent game-changing announcements by medical technology company MedX Health (MedX Health Stock Quote, Chart, News TSXV:MDX). That scenario, said Cooper in a June 16 update to clients, makes for a prime investmen ...

Profound Medical is insulated from COVID-19, says Raymond James

Looking for bright spots within the ongoing market deluge? Raymond James analyst Rahul Sarugaser says Profound Medical (Profound Medical Stock Quote, Chart, News TSX:PRN) should be top of mind, as the company appears to be well-insulated with respect to the COVID-19 pandemic. In an update to client ...

CRH Medical has price target cut at Beacon Securities

CRH Medical Corporation (CRH Medical Corporation Stock Quote, Chart, News TSX:CRH) hung onto its “Buy” rating from Beacon Securities analyst Doug Cooper after disappointing fourth quarter results. The analyst reviewed the Q4 in an update to clients on Thursday and reduced his target by half. Va ...